{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T10:07:05Z","timestamp":1779530825406,"version":"3.53.1"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Myeloid sarcoma (MS) is an extramedullary tumor of immature myeloid cells that can precede or accompany acute myeloid leukemia (AML). Mediastinal\/retroperitoneal involvement causing esophageal compression is rare and prone to misdiagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 67-year-old woman presented with 20 days of progressive dysphagia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Contrast-enhanced Computed tomography showed infiltrative soft-tissue masses in the posterior mediastinum, para-aortic region, and bilateral chest\/abdominal walls, encasing the esophagus and major vessels; endoscopy confirmed extrinsic esophageal stenosis. EUS-FNA was nondiagnostic for small-cell carcinoma. Core biopsy with high-power review revealed predominantly medium-to-large blasts with focal granulocytic maturation. Immunophenotype supported myeloid lineage: MPO diffuse positive; CD117 positive; focal CD34 and CD99; weak-to-focal CD45\/LCA; negative B-cell (CD19, CD20, CD79a), T-cell (CD2, CD3, CD5, CD7), and epithelial markers (CK AE1\/AE3, CK19). Ki-67 proliferation rate was 40%\u201350%. Peripheral blood counts were unremarkable for blasts or cytopenias; bone marrow aspirate\/biopsy\/flow showed no diagnostic evidence of AML. Final diagnosis: MS with extrinsic esophageal compression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>AML-type systemic chemotherapy with the HAA regimen (homoharringtonine 3\u2009mg d1\u20137, aclarubicin 20\u2009mg d1\u20137, cytarabine 0.2\u2009g d1\u20137; q3 weeks) plus standard supportive care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Dysphagia improved during the first cycle. Interval imaging demonstrated reduction of mediastinal\/retroperitoneal soft-tissue bulk and improved esophageal lumen consistent with disease control. No radiotherapy or esophageal stenting was required. On follow-up, disease remained controlled without transformation to AML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Infiltrative mediastinal\/retroperitoneal MS may present with esophageal obstruction and mimic lymphoma or carcinoma. High-index suspicion, targeted biopsy with high-power morphology, and a focused immunohistochemical panel are critical for timely diagnosis and treatment initiation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046337","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T22:00:34Z","timestamp":1764972034000},"page":"e46337","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Extensive myeloid sarcoma presenting with esophageal compression and dysphagia as the initial manifestation"],"prefix":"10.1097","volume":"104","author":[{"given":"Haoyu","family":"Li","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Pathology, Qilu Hospital of Shandong University, Jinan, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Qilu Hospital of Shandong University, Jinan, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2995-3270","authenticated-orcid":false,"given":"Yanbo","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260523","doi-asserted-by":"crossref","first-page":"100773","DOI":"10.1016\/j.blre.2020.100773","article-title":"Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: a tale of misnomers, controversy and the unresolved.","volume":"47","author":"Shallis","year":"2021","journal-title":"Blood Rev"},{"key":"R2-20260523","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.5858\/2006-130-1570-GSOTSI","article-title":"Granulocytic sarcoma of the small intestine.","volume":"130","author":"Kohl","year":"2006","journal-title":"Arch Pathol Lab Med"},{"key":"R3-20260523","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.biopha.2012.10.014","article-title":"Is there a \u201cgold\u201d standard treatment for patients with isolated myeloid sarcoma?","volume":"67","author":"Antic","year":"2013","journal-title":"Biomed Pharmacother"},{"key":"R4-20260523","first-page":"507","article-title":"Small bowel obstruction as a presenting sign of granulocytic sarcoma.","volume":"13","author":"Sivan-Hoffmann","year":"2011","journal-title":"Isr Med Assoc J"},{"key":"R5-20260523","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/MOH.0000000000000571","article-title":"Myeloid sarcoma.","volume":"27","author":"Shahin","year":"2020","journal-title":"Curr Opin Hematol"},{"key":"R6-20260523","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/10245332.2017.1333275","article-title":"Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years.","volume":"23","author":"Kaur","year":"2018","journal-title":"Hematology"},{"key":"R7-20260523","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.5858\/arpa.2012-0537-OA","article-title":"Myeloid sarcoma of the head and neck region.","volume":"137","author":"Zhou","year":"2013","journal-title":"Arch Pathol Lab Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T10:01:13Z","timestamp":1779530473000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":7,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046337","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"2025-07-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}